Do molecular diagnostics add to clinical characteristics in selecting patients for gefitinib treatment?
- PMID: 17955045
- DOI: 10.1038/ncponc0997
Do molecular diagnostics add to clinical characteristics in selecting patients for gefitinib treatment?
Comment on
-
Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial.J Clin Oncol. 2007 Jun 1;25(16):2248-55. doi: 10.1200/JCO.2006.09.4300. J Clin Oncol. 2007. PMID: 17538169 Clinical Trial.
Publication types
LinkOut - more resources
Full Text Sources